ALX Oncology Holdings Inc. Common Stock (ALXO) Stock
Fundamentals
Recent news

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
ALXO

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
ALXO

ALX Oncology Q1 Earnings Call Highlights
ALX Oncology Q1 Earnings Call Highlights
ALXO

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
ALXO
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
% positive news of 4 articles
published over the past 14 days
Latest news

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
ALXO

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
ALXO

ALX Oncology Q1 Earnings Call Highlights
ALX Oncology Q1 Earnings Call Highlights
ALXO

Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
ALXO
About ALX Oncology Holdings Inc. Common Stock
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jason W. Lettmann | CEO & Director | 1977 |
| Mr. Harish Shantharam C.F.A. | Chief Financial Officer | 1981 |
| Ms. Shelly Wong CPA | Senior VP of Finance & Chief Accounting Officer | 1977 |
| Dr. Barbara J. Klencke M.D. | Chief Medical Officer | 1957 |
| Mr. Jeff E. Knight M.P.H. | Chief Development & Operating Officer | 1972 |
| Mr. Michael Listgarten | General Counsel | — |
| Dr. Athanasios Tsiatis M.D. | Senior Vice President of Clinical Development | — |
| Dr. Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety & Pharmacovigilance | — |
| Ms. Lisa Sauer | Senior Vice President of Regulatory Affairs & Quality Assurance | — |
| Ms. Sue Naim | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
0 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +25.6 | -5.2 | -14.1 | +12.4 | +15.0 | -5.8 | +0.0 | -33.8 |



